120 related articles for article (PubMed ID: 34666894)
1. Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma.
Nagore E; Virós A; Kumar R
J Invest Dermatol; 2022 Feb; 142(2):279-281. PubMed ID: 34666894
[TBL] [Abstract][Full Text] [Related]
2. Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
Nardin C; Laheurte C; Puzenat E; Boullerot L; Ramseyer M; Marguier A; Jacquin M; Godet Y; Aubin F; Adotevi O
J Invest Dermatol; 2022 Feb; 142(2):435-444. PubMed ID: 34352265
[TBL] [Abstract][Full Text] [Related]
3. Distinct prognostic value of circulating anti-telomerase CD4
Laheurte C; Dosset M; Vernerey D; Boullerot L; Gaugler B; Gravelin E; Kaulek V; Jacquin M; Cuche L; Eberst G; Jacoulet P; Fabre E; Le Pimpec-Barthes F; Tartour E; De Carvalho Bittencourt M; Westeel V; Adotévi O
Br J Cancer; 2019 Aug; 121(5):405-416. PubMed ID: 31358938
[TBL] [Abstract][Full Text] [Related]
4. Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4 + Th1 Response in Metastatic Non-Small Cell Lung Cancer.
Wespiser M; Marguier A; Lecoester B; Richard T; Boullerot L; Malfroy M; Kumar A; Laheurte C; Adotévi O
J Immunother; 2023 Sep; 46(7):279-283. PubMed ID: 36799899
[TBL] [Abstract][Full Text] [Related]
5. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
[TBL] [Abstract][Full Text] [Related]
6. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
Dosset M; Godet Y; Vauchy C; Beziaud L; Lone YC; Sedlik C; Liard C; Levionnois E; Clerc B; Sandoval F; Daguindau E; Wain-Hobson S; Tartour E; Langlade-Demoyen P; Borg C; Adotévi O
Clin Cancer Res; 2012 Nov; 18(22):6284-95. PubMed ID: 23032748
[TBL] [Abstract][Full Text] [Related]
7. Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.
Laheurte C; Galaine J; Beziaud L; Dosset M; Kerzerho J; Jacquemard C; Gaugler B; Ferrand C; Dormoy A; Aubin F; Jacoulet P; Westeel V; Borg C; Tartour E; Godet Y; Maillère B; Adotévi O
Oncoimmunology; 2016 May; 5(5):e1137416. PubMed ID: 27467955
[TBL] [Abstract][Full Text] [Related]
8. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro.
Wesa A; Kalinski P; Kirkwood JM; Tatsumi T; Storkus WJ
J Immunother; 2007 Jan; 30(1):75-82. PubMed ID: 17198085
[TBL] [Abstract][Full Text] [Related]
9. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
10. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
Li H; Li J; Zhang C; Zhang C; Wang H
Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393
[TBL] [Abstract][Full Text] [Related]
11. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.
Yamaguchi K; Mishima K; Ohmura H; Hanamura F; Ito M; Nakano M; Tsuchihashi K; Ota SI; Wada N; Uchi H; Ariyama H; Kusaba H; Niiro H; Akashi K; Baba E
Cancer Sci; 2018 Oct; 109(10):3032-3042. PubMed ID: 30066977
[TBL] [Abstract][Full Text] [Related]
12. Telomerase and CD4 T Cell Immunity in Cancer.
Dosset M; Castro A; Carter H; Zanetti M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32630460
[TBL] [Abstract][Full Text] [Related]
13. Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.
Kiniwa Y; Li J; Wang M; Sun C; Lee JE; Wang RF; Wang HY
PLoS One; 2015; 10(5):e0124094. PubMed ID: 25993655
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
15. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J
J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150
[TBL] [Abstract][Full Text] [Related]
16. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
19. Anti-Telomerase CD4
Spehner L; Kim S; Vienot A; François E; Buecher B; Adotevi O; Vernerey D; Abdeljaoued S; Meurisse A; Borg C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957741
[TBL] [Abstract][Full Text] [Related]
20. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
Datta J; Fracol M; McMillan MT; Berk E; Xu S; Goodman N; Lewis DA; DeMichele A; Czerniecki BJ
JAMA Oncol; 2016 Feb; 2(2):242-6. PubMed ID: 26719971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
